•
PH
PHIO
Phio Pharmaceuticals Corp. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
11.63M
Volume
383.16K
52W High
$4.19
52W Low
$0.97
Open
$1.06
Prev Close
$1.08
Day Range
1.01 - 1.07
About Phio Pharmaceuticals Corp. Common Stock
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Latest News
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
GlobeNewswire Inc.•Aug 20
Phio Posts Wider Loss in Fiscal Q2
The Motley Fool•Aug 14
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033
GlobeNewswire Inc.•Aug 23
Phio Pharmaceuticals Secures New Investor
GlobeNewswire Inc.•May 17
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
GlobeNewswire Inc.•May 15
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
GlobeNewswire Inc.•May 9
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
GlobeNewswire Inc.•Apr 30
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
GlobeNewswire Inc.•Apr 22